Compare ADMA Biologics Inc (ADMA) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs International Business Machines Corp — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while International Business Machines Corp trades at $301.2 (market cap $287.73B). The key difference: International Business Machines Corp is far larger — about 135.1× ADMA Biologics Inc's market cap, and International Business Machines Corp pays a 2.21% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | IBM | |
|---|---|---|
Market Cap | $2.13B | $287.73B |
Sector | Health | Technology |
52-Week High | $20.38 | $329.23 |
52-Week Low | $7.60 | $214.64 |
Enterprise Value | $2.20B | $345.75B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
IBM's stock trades at $306.13, up 5.74% today, and is near its consensus price target of $308.14. The technical outlook is bullish with strong moving average signals, though the 6-day RSI indicates overbought conditions. Fundamentally, the company reported revenue of $67.54B in 2025 with a net income margin of 15.61%, and it has beaten earnings estimates for the last three quarters. Recent news highlights product launches in AI and quantum computing.
The outlook is positive with continued earnings momentum and strategic focus on high-growth areas like AI and hybrid cloud. Key risks include competitive pressures in technology and execution challenges in innovation. Analyst sentiment is mixed but leans bullish, with 47% buy ratings. The stock offers a dividend yield supported by strong cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
